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Background: Cancer diagnosis in both dogs and humans is complicated by the lack of a non-invasive diagnostic
test. To meet this clinical need, we apply the recently developed immunosignature assay to spontaneous canine
lymphoma as clinical proof-of-concept. Here we evaluate the immunosignature as a diagnostic for spontaneous
canine lymphoma at both at initial diagnosis and evaluating the disease free interval following treatment.
Methods: Sera from dogs with confirmed lymphoma (B cell n = 38, T cell n = 11) and clinically normal dogs
(n = 39) were analyzed. Serum antibody responses were characterized by analyzing the binding pattern, or
immunosignature, of serum antibodies on a non-natural sequence peptide microarray. Peptides were selected
and tested for the ability to distinguish healthy dogs from those with lymphoma and to distinguish lymphoma
subtypes based on immunophenotype. The immunosignature of dogs with lymphoma were evaluated for individual
signatures. Changes in the immunosignatures were evaluated following treatment and eventual relapse.
Results: Despite being a clonal disease, both an individual immunosignature and a generalized lymphoma
immunosignature were observed in each dog. The general lymphoma immunosignature identified in the initial
set of dogs (n = 32) was able to predict disease status in an independent set of dogs (n = 42, 97% accuracy). A
separate immunosignature was able to distinguish the lymphoma based on immunophenotype (n = 25, 88%
accuracy). The individual immunosignature was capable of confirming remission three months following diagnosis.
Immunosignature at diagnosis was able to predict which dogs with B cell lymphoma would relapse in less than
120 days (n = 33, 97% accuracy).
Conclusion: We conclude that the immunosignature can serve as a multilevel diagnostic for canine, and potentially
human, lymphoma.
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Clinical diagnosis of cancer is a complex process usually
initiated by presentation of indicative symptoms. Suspected
conditions are identified as possible differential diagnosis
and a battery of blood tests, urinalysis, imaging tests, and
biopsy are conducted before final diagnosis is made.
Biomarkers have been identified for some cancers, but have
limited use as a primary screening tool. A single blood test
capable of diagnosing cancer with high sensitivity and
specificity would enhance patient care by streamlining the
diagnostic process. Non-Hodgkin lymphoma (NHL) is a
spontaneously occurring neoplasm of particular interest.* Correspondence: Stephen.Johnston@asu.edu; Bart.Legutki@asu.edu
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unless otherwise stated.NHL newly affects approximately 70,000 people annually
in the United States [1] and has had a steadily increasing
incidence in the United States and Europe [2]. If diagnosed
early, effective treatments can be selected [2,3] and the
5 year survival is 72% [1]. However, diagnosis is compli-
cated by the lack of a non-invasive test and is presently
made by clinical signs, physical examination findings and
imaging, with confirmation of disease by biopsy. Even
with effective treatment, 50% of patients with aggressive
lymphomas have residual disease and eventually relapse
[4]. A serological test for monitoring lymphoma would
have utility at multiple stages: early detection, diagnosis
and monitoring of residual disease. Spontaneous canine
lymphoma (LSA) and human NHL have nearly identical
presentations and pathologies [5-7], making them idealal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tics. Dogs have been used as predictive models for human
oncology in multiple cancers [8], including lymphoma
[9,10]. Here we explore the application of the immuno-
signature diagnostic to canine LSA.
Lymphoma is one of the most commonly encountered
canine neoplasms, generally affecting middle-aged to older
dogs. Breeds reported to be at increased risk include
boxers, bull mastiffs, Bassett hounds, Saint Bernards,
Scottish terriers, Airedales, golden retrievers and English
bulldogs [11]. Typically dogs present with an aggressive
high-grade multicenteric lymphoma, of which diffuse
large B-cell lymphoma (DLBCL) is the most common
subtype [5]. Following chemotherapy, 95% all dogs relapse
following a period of remission. While approximately 85%
of dogs present with multicentric peripheral lymphaden-
opathy, a small percentage present with visceral disease
only (e.g. primary mediastinal, gastrointestinal or hepatos-
plenic forms), which requires serial imaging in order to
monitor remission status. In humans, remission status is
monitored by CT, MRI or PET scans [2]. Facile and early
detection of relapse may facilitate re-induction of remission
and improve outcome. Here, we evaluate the immuno-
signature diagnostic technology relative to these diagnostic
requirements.
A serological test would facilitate routine monitoring
during an annual wellness examination, enable faster
diagnosis when LSA is suspected and allow monitoring
following treatment. Design of such a test is dependent
on the identification of an appropriate biomarker. Ideally,
this test would be applicable to early disease, but to do so
it must overcome the “blood dilution” problem: that is, if
106 initiating cancer cells release 1000 molecules each of a
biomarker into two liters of blood at steady state, the con-
centration of this biomarker would only be 1.3 × 10−14 M
[12], placing it below the detection limits of even the best
assays [12]. Antibodies are an ideal solution to this prob-
lem. Self-reactive antibodies have been reported in cancer
and autoimmune disease [13,14]. Arising early in the
course of a disease, the activation of a single B cell results
in an ~1011 amplification of signal in only a week [15].
Furthermore, antibodies are stable in blood, enabling
archived samples to be used in assay development or
serial monitoring [16,17].
We have developed a technology termed immunosigna-
tures which displays the circulating antibody repertoire
upon an addressable, machine readable random peptide
microarray (reviewed in [18]). The random sequences
allow an unbiased display of all types of antibody binding.
The peptides on the microarray serve as mimetics of the
actual epitopes and capitalize on the cross-reactivity of
antibodies. Even if the actual epitope is not present,
another peptide that the same antibody can bind will be
present. In addition, the arrays are inexpensive and can beadapted to high throughput sample processing. Thus far
we have been able to distinguish over thirty diseases from
healthy individuals with high accuracy and specificity.
Antibodies are detected earlier by the immunosignature
than an ELISA in infectious disease [18], an immuno-
signature of Alzheimer’s disease in mouse models is
evident months before symptoms begin [19], and vaccine
efficacy can be predicted using immunosignatures [20].
The immunosignature is capable of distinguishing types of
brain tumor pathologies and molecular subtypes which
would otherwise only be diagnosable by biopsy [21]. Each
of these distinctions was made using the same immu-
nosignature microarray using species-specific detection
reagents. The characteristics of immunosignature diag-
nostics have been reviewed [18].
In this study we assess the ability of the immunosignature
to characterize the humoral response to canine LSA and
investigate its clinical utility in diagnosing different subtypes
of disease. Pretreatment serum samples from patients
presenting with T cell and B cell LSA (LSA-T and LSA-B)
are compared to healthy dogs. Serial serum samples from
patients that experienced remission following chemother-
apy and ultimately relapsed were investigated. Immuno-
signatures informative for each subtype of disease and
their diagnostic efficacy are reported.Methods
Study plan
The diagnosis and treatment of many cancers, including
canine and human LSA, is complicated by the lack of a
non-invasive serological test. Having demonstrated that the
immunosignature is capable of simultaneously classifying
human cancers including multiple subtypes of brain cancer
[21], we hypothesized that the immunosignature could be
applicable to canine LSA. The Colorado State University
tumor archive was canvassed to select sera from 38 B cell
LSA, 11 T cell LSA and 39 clinically healthy dogs collected
as part of ongoing prospective archiving efforts. Summary
statistics of age, breed and clinical presentation are de-
scribed in Table 1.Patient sera
Serum samples were obtained from clinically normal
client-owned dogs or dogs with histologically or cyto-
logically confirmed LSA and stored at −80°C from the
time of presentation, prior to any specific therapy, and
were collected with owner consent and approval of the
CSU Institutional Animal Care and Use Committee
(Protocol #10-2007A). Samples were collected during
routine visits under nominal clinical conditions. In a
subset of patients, sera were collected serially from dogs
with LSA at each subsequent recheck visit, up to and
including the time of relapse.
Table 1 Summary of study population signalment1
Class N Age2 Sex3 Breed
Healthy 39 6 (2 to 15) M 24 Mixed Breed (19), Golden Retriever (6), Labrador Retriever (3), Staffordshire Terrier (2), Australian Cattle Dog (2),
Australian Shepherd, Dalmatian, Doberman, German Wire Haired Pointer, Std. Poodle, St. Bernard, Rottweiler
F 15
LSA-B 38 7.9 (2 to 13) M 22 Mixed Breed (10), Golden Retriever (5), Border Collie (4), German Shepard (2), Rottweiler (2), Scottish Terrier (2),
Vizsla (2), Bassett Hound, Belgian Malinois, Boxer, Chesapeake Bay Retriever, Collie, Doberman, Labrador
Retriever, Miniature Schnauzer, Sheltie, Staffordshire Terrier, OtherF 16
LSA-T 11 6.97 (4 to12) M 4 Golden Retriever (3), Boxer (3), Mixed Breed (2), Bull Mastiff, Irish Setter, Labrador Retriever
F 7
1Archived serum samples from client owned dogs presenting to the Animal Cancer Center at Colorado State University were used.
2Median age is presented with the range, low to high, in parenthesis.
3Neutered and intact dogs are totaled under the appropriate sex.
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The CIM10Kv2 random peptide microarrays used for
immunosignatures have been described previously [17,19].
These microarrays contain 10,000 random peptides
containing 17 random residues and an N-terminal CSG
linker. Known peptide sequences were piezo-electrically
printed in an addressable format with two printings of
the 10,000 peptides per standard slide. Arrays were
obtained from the Peptide Array Core at Arizona State
University (www.peptidearraycore.com). Two print runs
having a quality control technical cross batch correlation
of 0.67 were used for this study.
Binding sera to the immunosignature arrays
Patient serum was used to probe the CIM10Kv2 immu-
nosignaturing microarray as described previously using
a Tecan HS4800 [17,21]. Prior to the assay, unbound
peptide was removed by prewashing the arrays in 7.33%
acetonitrile, 30% isopropanol and 0.5% trifluoracetic acid.
The arrays were then blocked in phosphate buffered saline
with 0.05% Tween 20 (PBST), 3% Bovine Serum Albumin
(BSA) and 0.014% mercaptohexanol for 1 hour. Following
washing with PBST, serum was diluted to 1:500 in incu-
bation buffer (PBST with 3% BSA) for 1 hour at 37°C.
Bound IgG was then detected using 5.0 nM anti-dog
IgG (Fc gamma specific)-Dylight 649 for 1 hour. Anti-Dog
IgG (gamma) from KPL was used in the first batch of
arrays and Anti-Dog IgG(gamma) from Jackson Immuno
Research was used in the second batch due to discontinu-
ation of the KPL conjugate. The microarrays were then
washed in PBST then distilled water. Nitrogen dried slides
were then scanned at 633 nm using an Agilent ‘C’ type
scanner at 100% laser power and 100% PMT.
Statistical analysis
Raw array images were aligned using GenePix (Molecular
Devices) to produce a tab deliminated results file. Physical
artifacts were removed by flagging the features as bad.
Results files were evaluated in GeneSpring (Agilent) or
Bioconductor R (3.0.1). For all analysis, the arrays run with
the KPL and the Jackson Immuno Research conjugateswere treated separately. The ComBat algorithm was used to
minimize assay batch effects on per chip median normal-
ized scores [22]. Background subtraction based on empty
features was applied to all replicates in a comparison as
needed. Criteria for selecting informative peptides between
classes were a Student’s T-test p value less than 0.05
with the Benjamani and Hochberg False Discovery
Rate (FDR) correction and a minimum fold change of
1.5× between class averages. A support vector machine in
R (e1071 library) [23] was used for classification with the
following settings type = C, Kernel = polynomial, degree = 2,
gamma = 0.1, coef0 = 1, epsilon = 0.1 and cost = 1. Iterative
testing was done in R by splitting the patient population
into 85% training for peptide selection and the remaining
15% into test sets to evaluate classification based on the
selected peptides, a minimum fold change of 10 between
classes was used for the iterative testing. Heatmaps were
generated in GeneSpring with individuals and peptides
clustered using the default Pearson correlation settings.
Principal component values were obtained in GeneSpring
and plotted in GraphPad Prism. Power analysis conducted
in R at 80% power, 5.0×10−6 significance level (FDR
adjusted p value), Standard deviation of 50%, and a 1.5
fold change (delta) between groups indicated a minimum
of 11 samples were needed for each comparison made. All
comparisons were adequately powered.
Results
The immunosignature distinguishes canine lymphoma
patients from healthy dogs
Initially, the immunosignature was evaluated with a
small set of dogs to determine the ability to distinguish
LSA (either B or T cell) from healthy. Patient (n = 21) and
healthy dog (n = 11) sera were randomized and applied to
the CIM10Kv2 array. Per chip median normalized values
were ComBat normalized to remove batch effects and
then compared between LSA and healthy dogs. A Student’s
T-test selected 340 peptides having an FDR corrected p
value less than 0.05 and a minimum 1.5 fold difference
in intensity between classes. Reactivity is shown in the
heatmap in Figure 1A. Separation of healthy and LSA is
Figure 1 The immunosignature distinguishes canine lymphoma patients from healthy dogs. A Student’s T-test (p < 0.05 with FDR) and a
1.5 fold change between classes was used to select 340 informative peptides. The distribution of intensities is shown in the Heatmap (A). Colors
represent the per peptide median normalized intensities. Yellow indicates the median, red five-fold above the median and blue 0.25 fold below the
median. Each row represents a peptide and each column represents and individual. Individuals were clustered in GeneSpring using the Pearson
correlation to each other. Variation among individuals based on the 340 peptides is shown in the PCA plot (B) where the first two principal
components are plotted. The classification efficacy is plotted in the ROC curve in (C). Print run one and the KPL conjugate were used for this assay.
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Figure 1B. Leave one out cross validation (LOOCV) was
able to separate LSA and healthy with 94% accuracy. A
receiver-operator characteristic (ROC) curve is shown
in Figure 1C. A similar distinction was made using the
CIM10Kv1 array, which is comprised of a separate pep-
tide library (data not shown). This demonstrates that
the immunosignature can distinguish canine LSA patients
from healthy dogs.
The immunosignature predicts health status in an
independent set of dogs
To test the predictive ability of the peptides identified
above, additional LSA-B patients (n = 20) and healthy
donors (n =22) were obtained. Serum from all LSA-B
patients (n = 38) and healthy donors (n = 39) wererandomized and used to probe the CIM10Kv2. Technical
requirements necessitated that serum from all dogs be
run on a second print run of the CIM10Kv2 and detected
using a different secondary antibody due to product
discontinuation by the original supplier. The 340 peptides
selected above to separate LSA and healthy clearly
separated the expanded test set of dogs, even though
the print run and anti-IgG secondary antibody were
different (Additional file 1: Figure S1). When the training
set arrays from print run 1 were used to predict the test
set from print run 2, the accuracy was 97%: one LSA-B
patient was miscalled as healthy. This accuracy was the
same whether the training set arrays were from the same
or different batch than the test set.
To exclude the possibility that the distinction between
LSA and healthy was an artifact of this division of training
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training (85%) and test (15%) sets. The training set was
used to select peptides having a p value < 0.05 with FDR
and a minimum fold change between classes of 10.0 fold.
The peptides were then used to train an SVM and predict
class membership of the test set. Over 10,000 randomiza-
tions into training and test sets, the median performance
on the test set accuracy was 92 +/− 9.6%, sensitivity was
100 +/− 12.2% and specificity was 83 +/− 14.3%. The
lower specificity was due to 3 healthy dogs that were
consistently miscalled when included in the test set
(Additional file 1: Table S1). To assess how much of the
immunosignature is due to other factors, all healthy
and LSA-B dogs were combined and divided based on
gender and age. Separation of dogs into two classes
based on age (division was 7 years old) yielded 14 sig-
nificant peptides that were unable to classify the dogs
on either a PCA or SVM. Further separation into male
and female dogs yielded one significant peptide that was
unable to classify in either a PCA or SVM. This suggests
that the difference in immunosignature based on health or
disease is due to the LSA and not other factors. Taken to-
gether, this demonstrates that the immunosignature is
both capable of predicting an independent test set and is
stable across array print runs and detection systems.
The immunosignature can distinguish dogs with t cell
lymphoma from those with b cell lymphoma
In dogs, LSA-T tends to be a more aggressive form of
LSA than LSA-B [24], and determining this distinction
can have impacts on both outcome and, in some cases,
choice of treatment [25]. For this reason, immunopheno-
typing is commonly performed as part of initial staging
in dogs with LSA. The immunosignature of the LSA-B
(n = 14) and LSA-T (n =11 ) patients were compared
using a Student’s T-test, and 47 peptides had a p value
less than 0.05 with FDR and a minimum 1.5 fold difference
between classes. Reactivity is shown in the heatmap in
Figure 2A. Separation of LSA-B and LSA-T is shown in the
PCA in Figure 2B. Leave one out cross validation was able
to separate LSA and healthy with 88% accuracy: one mem-
ber of each class was misidentified. A ROC curve is shown
in Figure 2C. Interestingly, one of the serum samples
initially identified as from a LSA-B patient clustered with
the LSA-T patients and classified as a LSA-T patient. This
patient was subsequently confirmed to have a CD3 positive
LSA. A similar distinction was made using the CIM10Kv1
arrays (data not shown). This demonstrates that the immu-
nosignature can distinguish LSA of B and Tcell origin.
Characterization of the individual lymphoma
immunosignature
Lymphoma is a clonal disease arising from the uncon-
trolled proliferation of a single lymphocyte [3]. We haveobserved individual immunosignatures in human myeloma,
another clonal B cell disease (Stafford et al. in preparation).
This raises the possibility of an immunosignature for each
LSA patient in addition to the general class immunosigna-
ture. Such an immunosignature could be either from the
antibody species produced by the B cell or the immune
response to the surface markers or other cancer related
antigens of the LSA cell. In the case of LSA-T there could
be a unique antibody response to the T cell receptor of the
LSA clone. Pattern matching analysis was done to identify
peptides uniquely recognized by each dog.
To reduce the influence of recent vaccines or infections,
the peptides with the least variability in healthy donors
(bottom quartile ranked on CV) were analyzed. The pat-
tern used was the per peptide median for all dogs except
the LSA patient being queried for which the value was set
at 5 fold above the per peptide median. Peptides matching
the profile with a Pearson correlation greater than 0.90
were defined as unique to that individual. A heatmap of
the unique peptides is presented in Figure 3A. The median
number of peptides identified in the LSA-B dogs was 8
(range: 3 to 71) and the median number of identified
peptides in the LSA-T patients was 6 (range: 2 to 6). No
peptides matching these profiles were bound in the
healthy dogs. If these unique peptides are bound by a
single antibody clone, then a motif could be present in the
peptide list. Sequence motifs were identified using the
GLAM2 algorithm and representative motifs are presented
as logo plots in Figure 3B and C. Individual immunosigna-
tures with associated motifs were also seen on the
CIM10Kv1 (not shown). Taken together, these data agree
with the clonal nature of the disease and suggest that the
individual immunosignature may be the result of a single
antibody clone, whether that produced by the involved B
cell clone or to a unique antigen such as the BCR or TCR
idiotype.
Monitoring the immunosignature present at diagnosis
marks remission but not relapse
To determine if the immunosignature could be used to
monitor patients for early signs of relapse, we obtained
sera from 12 dogs with LSA at the time of diagnosis,
3 months following treatment at which point they were
clinically in remission, and at the time of relapse. The
sera was run on the CIM10Kv2 and evaluated for changes
both personal and subtype immunosignatures. Comparison
of the individual immunosignatures between diagnosis and
remission indicated that a median of 72 percent of the
immunosignature decreased following initiation of treat-
ment (Table 2). This suggests that the individual LSA
immunosignature has utility in establishing or verifying
remission. However, the antibody reactivity level of these
peptides did not return to the level observed in normal
dogs. This suggests that the immune response generated
Figure 2 The immunosignature distinguishes LSA-B from LSA-T. A Student’s T-test (p < 0.05 with FDR) and a 1.5 fold change between classes
were used to select 47 informative peptides. The distribution of intensities is shown in the Heatmap (A). Colors represent the per peptide median
normalized intensities. Yellow indicates the median, red five-fold above the median and blue 0.25 fold below the median. Each row represents a
peptide and each column represents and individual. Individuals were clustered in GeneSpring using the Pearson correlation to each other. Variation
among individuals based on the 47 peptides is shown in the PCA plot (B), where the first two principal components are plotted. The classification
efficacy is plotted in the ROC curve in (C). Print run one and the KPL conjugate were used for this assay.
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of cells that lead to the recurrence. Peptides decreasing at
remission did not also increase at relapse. Survival of the
minimal residual disease cells and the lack of the return of
decreased peptides to pre-treatment levels suggest that
the tumor could have been kept in check by the immune
umbrella of the original tumor but new antigens and path-
ways enabled relapse.
The subtype immunosignature was defined as the pep-
tides increased in each phenotype. For the 177 peptides
increased in LSA-B, a median of 25 +/− 14 peptides (14%)
decreased at remission and 13 +/− 7 peptides increased
from remission to relapse. Of the 173 peptides increased
in LSA-T, a median of 35 +/− 20 peptides (20%) decreased
upon remission and a median of 21.4 +/− 6 peptides
(12%) increased between remission and relapse.Antibodies binding the subtype specific immunosignature
were likely raised by a normal B cells against the LSA cell
as part of the anti-LSA immune response. Clinical therapy
either excises or chemically kills the LSA cell, removing
the antigen that stimulated the normal B cell. Persistence
of the immunosignature after removal of the LSA cell
suggests that the normal B cell had differentiated to a long
lived plasma cell and was unaffected by remission. Taken
together, this indicates that the immunosignature can
verify remission through the personalized signature, but
other means are needed to detect recurrence.
Further characterization of the B Cell lymphoma
immunosignature
Retrospective surveys of LSA-T and LSA-B identified
median DFIs of 2.5 months for LSA-T and 6.74 months
Figure 3 Individual lymphoma signatures. (A) Peptides comprising the unique elements of the immunosignatures of canine lymphoma
patients are displayed in a false color heatmap. Red represents 5 fold greater than median, yellow represents the median and blue 5 fold below
the median. Peptides ranked in the lowest quartile for coefficient of variation among healthy dogs were analyzed by correlation (greater than
Pearson R of 0.9) to a recognition profile of 10 fold above the median in an individual and at the median for both healthy dogs and lymphoma
patients. The GLAM2 pattern-matching algorithm was used to establish patterns for each dog. Representative patterns for LSA-B are shown in
(B & C). Print run one and the KPL conjugate were used for this assay.
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this study and in clinical practice, dogs with LSA-B tended
to have a higher proportion of survivors at later months
[24], indicating a need to further characterize the LSA-B
immunosignature. The median raw feature intensity of ar-
rays probed with serum from LSA-B patients and healthy
donors were compared. The median raw feature intensity
of the arrays probed with LSA-B were significantly lower
(p = 1×10−4) than those probed with healthy donors. In
prior studies we noted overall feature intensity increases
in infection and as the concentration of antibodies applied
to the array increases [15]. This suggests that either the
overall amount of immunoglobulin or reactivity is de-
pressed in LSA-B patients, fitting with clinical studies of
NHL in humans, which report serum hypogammaglobem-
mia in 10 to 15% of patients [26,27] and a 21% reduction
of crude median IgG levels in DLBCL patients [27].The immunosignature of B Cell LSA at diagnosis is
capable of predicting length of disease free interval in
dogs entering remission
Since changes in the individual or class immunosignatures
following treatment were not indicative of relapse, we
sought to determine if the immunosignature at diagnosis
could predict time to relapse. The LSA-B patients were
divided into those that relapsed in under 120 days (n = 10)
and those that had a delayed relapse of over 120 days
(n = 23). A Student’s T-test identified 35 peptides with a
p value <0.05 with FDR between classes. A heatmap of the
selected peptides is presented in Figure 4A. Separation of
the patients based on DFI is presented in the PCA plot
shown in Figure 4B. Note that the dogs having a longer
DFI cluster more tightly than those with a short DFI,
having median Mahalanobis distances to the class means
of 13.66 and 17.27 respectively, indicating less variance in
Table 2 Change in the individual immunosignature between diagnosis and reoccurrance1
Portion of the signature
decreasing by 3 months2
Portion of signature returning to
pretreatment Levels at relapse3
Individual Type4 DFI (days)5 Peptides6 Number7 Percent8 Median fold
change at day 90
Number Percent Median fold
change vs day 0
247690 B 174 3 0 0 1.21 0 0 0.78
248661 B 280 5 1 20 0.85 0 0 0.59
251332 B 273 10 7 70 0.59 0 0 0.42
251661 B 119 71 65 92 0.42 5 7 0.37
252343 B 257 11 9 82 0.46 1 9 0.49
253509 B 270 7 7 100 0.45 0 0 0.20
256744 B 112 3 1 33 0.87 1 33 0.94
257195 B 333 4 3 75 0.69 1 25 0.45
219623 T 185 2 1 50 0.78 1 50 0.95
238300 T 167 5 4 80 0.54 0 0 0.49
243388 T 270 3 3 100 0.37 3 100 1.42
251702 T 71 6 0 0 1.37 0 0 1.40
1The individual signature is defined as the number of peptides uniquely recognized by each individual compared to other dogs in the study.
2The number of peptides in the individual immunosignature that decreased in normalized RFI greater than the minimum detectable fold change of 0.76.
3The number of peptides with a normalized RFI that returned to within the minimum detectable fold change of 0.76 to 1.3x of the values at diagnosis by the time
they were clinically out of remission.
4Phenotype of the lymphoma, B cell or T cell.
5Time between initiation of treatment and being clinically defined as out of remission.
6The number of peptides comprising the individual immunsignature.
7The number of peptides comprising the individual immunsignature that decreased at three months.
8Percent of the individual immunosignature that decreased at three months.
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immunosignature. An SVM trained on the 35 peptides
has a LOOCV accuracy of 97%. A ROC curve is presented
in Figure 4C. This demonstrates that the immunosigna-
ture is capable of predicting the length of DFI at the time
of diagnosis.
Discussion
It has been well established that most cancers are capable
of generating detectable cellular and humoral immune
responses, although they are insufficient to control the
disease. This observation has led to the exploration of
immune-based cancer therapies in humans and dogs,
including in canine LSA [28-31]. In the present study
we have used immunosignatures to characterize canine
LSA and evaluated the immunosignature technology as
a diagnostic. We have demonstrated that canine LSA
patients can be readily distinguished from healthy dogs.
The immunosignature of LSA was capable of predicting
an independent test set with high accuracy and was robust
to print run and detection system changes. Furthermore,
the distinction between B and T-cell LSA was able to be
determined from the immunosignature. Individualized
immunosignatures were also observed in the LSA patients
at diagnosis, which declined as patients entered remission.
The individualized immunosignature did not return at
relapse for all dogs; however, the immunosignature at
diagnosis was capable of predicting the length of DFI.Taken together, this study demonstrates the clinical utility
of the immunosignature as a multilevel diagnostic for LSA.
Lymphoma is a clonal disease arising from an abnormally
proliferating B or T cell. Despite the clonal origin of the
disease, a LSA specific immunosignature was identifiable.
In humans, certain variable region genes are prevalent in
LSA [32-34] and superantigens are LSA associated [35],
raising the possibility that the immunosignature is that of a
causal immunological insult. Proteomic studies in humans
have identified distinct protein expression profiles that are
informative not only for LSA, but clinical subtype [36,37].
This raises the possibility that the immunosignature is
reflecting cancer antigens associated with LSA. In individ-
ual dogs, an individual immunosignature was additionally
detected and may be the product of the individual B cell
clone while the class immunosignature was reflective of the
underlying cancer biology. The influence of the antibody
produced by the individual B cell clone is reflected in the
immunosignature distinguishing LSA-B and LSA-T, where
the LSA-T patients cluster together much more tightly on
the PCA than do LSA-B patients. It is of note that the indi-
vidual signature may indicate the number of peptides
bound per antibody.
We observed that the personalized immunosignature
declined as the dog entered remission along with the
common LSA-B signature fits with what is known of this
cancer. The causal B cell clone that forms the LSA is
present in abundance at diagnosis and is excised or
Figure 4 The immunosignature at diagnosis can predict disease free interval. A Student’s T-test (p < 0.05 with FDR) and a 1.5 fold change
between classes was used to select 35 informative peptides. The distribution of intensities is shown in the Heatmap (A). Colors represent the per
peptide median normalized intensities. Yellow indicates the median, red two fold above the median and blue less than 0.8 fold below the median.
Each row represents a peptide and each column represents and individual. Individuals were clustered in GeneSpring using distance measurement to
each other. Variation among individuals based on the 35 peptides is shown in the PCA plot (B), where the first two principal components are plotted.
The classification efficacy is plotted in the ROC curve in (C). Print run two and the Jackson conjugate were used for this assay.
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sion, yet antibodies against the LSA persist. Serum IgG
in dogs has a half-life of 8 to 12 days [38], indicating
that at the three-month sampling, serum levels of the
anti-LSA antibody species could have reduced to 1 to
6% of the diagnosis titer. This suggests that the anti-LSA
antibody response may have differentiated to long lived
plasma cells which have a 140 day half-life [39] and are
largely unaffected by immunosuppressive chemotherapy
[40,41]. That the personalized immunosignature did not
increase upon relapse suggests that either other antigens
are involved in triggering relapse of a dormant tumor cell,
somatic hypermutation has occurred, or the relapse is
actually a second clonal lineage initiating an antigenically
distinct LSA tumor. The disease free interval in both dogs
and humans is a period of watchful waiting, punctuated
with frequent recheck examinations, blood draws andimaging. The immunosignature at diagnosis is capable of
identifying dogs having an aggressive LSA that relapsed in
less than four months from those with a less aggressive
form.
Conversion of a microarray-based assay to a diagnostic
is reliant on the robustness of the platform to differences
in technician, print batch and detection system. In our
training and test set, we evaluated the sum effect of
these conditions. The training set was initially run as
one batch then repeated in the second batch with the
test set. When the SVM was trained using either training
set batch, the test set was predicted with >94% accuracy.
This demonstrates that as a practical diagnostic assay, a
single patient could be normalized to a co-run standard
and the immunosignature compared to a database, thereby
alleviating the impractical possibility of having to run a 60
sample training set with each assay. Further enabling the
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eluted from dried blood spots to perform in the immuno-
signature assay [17].
There are multiple other techniques that have been
established for the determination of immunophenotype
in canine LSA. These include immunohistochemistry,
immunocytochemistry, flow cytometry, and PCR for anti-
gen receptor rearrangement (PARR) [42]. While all are
associated with acceptable sensitivity and specificity, all
require tumor samples and thus would not be suitable
as a screening or early detection test. Real-time PCR of
peripheral blood, using reagents specific for a patient’s
particular antigen receptor gene rearrangement, has also
been used for remission status monitoring and relapse
detection in canine LSA [43,44]; however, this is labor
and time intensive and requires the generation of custom
tools for each patient, and would also not be suitable as a
screening test.
Conclusions
This study illustrates the immunosignature as an im-
provement over current veterinary serodiagnostics for
LSA. As opposed to tests which either non-specifically
indicate a cancer by measuring thymidine kinase activity
[45] or rely on biomarkers [46], the immunosignature is
information rich. From a single assay, the patient could
potentially be diagnosed as having LSA or not, whether
the LSA is of B or T cell lineage and whether the DFI
following chemotherapy will be short or long. Each of
these points of information is critical for the treating
veterinarian. A negative immunosignature for LSA aids
in the differential diagnosis, B cell LSA and T cell LSA
may be treated differently, and knowing at diagnosis that
the DFI will be short may provide important prognostic
information to the pet owner and veterinarian. Given
the similarity between both disease and immune system
function in dogs and humans, the immunosignature is
expected to provide the same information to physicians
and their patients.
Statement of translational relevance
This paper demonstrates that the serum antibody repertoire
produces a unique binding pattern or immunosignature for
lymphoma on a random peptide array. The immunosigna-
ture is descriptive for B or T cell lymphoma and estimating
duration of remission following treatment. Thus the immu-
nosignature has the capability to provide multiple levels of
prognostic information to the patient and clinician.Additional file
Additional file 1: The immunosignature of canine lymphoma:
characterization and diagnostic application supplemental material.Abbreviations
NHL: Non-Hodgkin lymphoma; LSA: B or T cell lymphoma; LSA-B: B cell
lymphoma; LSA-T: T cell lymphoma; DFI: Disease free interval; SVM: Support
vector machine; LOOCV: Leave one out cross validation; FDR: Benjamani and
Hochberg False Discovery Rate correction.
Competing interests
Stephen Albert Johnston wishes to disclose ownership in HealthTell, Inc and
Calviri, LLC, diagnostic chip companies.
Authors’ contributions
DT, SAJ and JBL designed the experiments. DT selected patient samples and
provided clinical context for the data analysis. JBL coordinated the experiments
and drafted the manuscript. SAJ and JBL analyzed the data. DT and SAJ critically
revised the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We wish to thank Kristen Siefert who assisted in running the arrays and Alex
Roesler who assisted in preliminary analysis of samples on the CIM10Kv1.0. John
Lainson and Zbigneiw Cichacz prepared the slides for printing. Jonathan
Reginold assisted with the signalment classifications.
Funding was provided by American Kennel Club Canine Health Foundation
grants CHF1651 to SAJ and DT and CHF1130 to Drs. Susan Lana and Anne Avery.
Author details
1Flint Animal Cancer Center, Colorado State University, 300 West Drake Road,
Fort Collins, CO 80523-1620, USA. 2Center for Innovations in Medicine, The
Biodesign Institute, Arizona State University, Tempe, AZ 85287-5901, USA.
Received: 28 April 2014 Accepted: 1 September 2014
Published: 8 September 2014
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63(1):11–30.
2. Shankland KR, Armitage JO, Hancock BW: Non-Hodgkin lymphoma. Lancet
2012, 380(9844):848–857.
3. Evans LS, Hancock BW: Non-Hodgkin lymphoma. Lancet 2003,
362(9378):139–146.
4. Larouche JF, Berger F, Chassagne-Clement C, Ffrench M, Callet-Bauchu E,
Sebban C, Ghesquieres H, Broussais-Guillaumot F, Salles G, Coiffier B:
Lymphoma recurrence 5 years or later following diffuse large B-cell
lymphoma: clinical characteristics and outcome. J Clin Oncol 2010,
28(12):2094–2100.
5. Marconato L, Gelain ME, Comazzi S: The dog as a possible animal model
for human non-Hodgkin lymphoma: a review. Hematol Oncol 2013,
31(1):1–9.
6. Ito D, Frantz AM, Modiano JF: Canine lymphoma as a comparative model
for human non-Hodgkin lymphoma: recent progress and applications.
Vet Immunol Immunopathol 2014, 159(3–4):192–201.
7. Richards KL, Motsinger-Reif AA, Chen HW, Fedoriw Y, Fan C, Nielsen DM,
Small GW, Thomas R, Smith C, Dave SS, Perou CM, Breen M, Borst LB, Stuter SE:
Gene profiling of canine B-cell lymphoma reveals germinal center and
postgerminal center subtypes with different survival times, modeling
human DLBCL. Cancer Res 2013, 73(16):5029–5039.
8. Paoloni M, Khanna C: Translation of new cancer treatments from pet
dogs to humans. Nat Rev Cancer 2008, 8(2):147–156.
9. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan
Z, Thamm DH, Miller RA, Buggy JJ: The Bruton tyrosine kinase inhibitor
PCI-32765 blocks B-cell activation and is efficacious in models of
autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010,
107(29):13075–13080.
10. London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M,
Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR,
McCauley D, Kauffman M, Shacham S: Preclinical evaluation of the novel,
orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in
spontaneous canine cancer: results of a phase I study. PLoS One 2014,
9(2):e87585.
11. Vail DM, Pinkerton ME, Young KM: Canine lymphoma and lymphoid
leukemias. In Small Animal Clinical Oncology. 5th edition. Edited by Withrow
SJ, Vail DM, Page RL. St. Louis, MO: Elsevier; 2013:608-367.
Johnston et al. BMC Cancer 2014, 14:657 Page 11 of 11
http://www.biomedcentral.com/1471-2407/14/65712. Hori SS, Gambhir SS: Mathematical model identifies blood biomarker-
based early cancer detection strategies and limitations. Sci Transl Med
2011, 3(109):109ra116.
13. Hu S, Vissink A, Arellano M, Roozendaal C, Zhou H, Kallenberg CG, Wong DT:
Identification of autoantibody biomarkers for primary Sjogren’s syndrome
using protein microarrays. Proteomic 2011, 11(8):1499–1507.
14. Mou Z, He Y, Wu Y: Immunoproteomics to identify tumor-associated
antigens eliciting humoral response. Cancer Lett 2009, 278(2):123–129.
15. Stafford P, Halperin R, Legutki JB, Magee DM, Galgiani J, Johnston SA:
Physical characterization of the “immunosignaturing effect”. Mol Cell
Proteomics 2012, 11(4):M111 011593.
16. AF Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, Schiller J, Lehtinen M,
Dillner J: Stability over time of serum antibody levels to human
papillomavirus type 16. J Infect Dis 1998, 177(6):1710–1714.
17. Chase BA, Johnston SA, Legutki JB: Evaluation of biological sample
preparation for immunosignature-based diagnostics. Clin Vaccine
Immunol 2012, 19(3):352–358.
18. Sykes KF, Legutki JB, Stafford P: Immunosignaturing: a critical review.
Trends Biotechnol 2013, 31(1):45–51.
19. Restrepo L, Stafford P, Johnston SA: Feasibility of an early Alzheimer’s
disease immunosignature diagnostic test. J Neuroimmunol 2012,
254(1-2):154–160. doi: 10.1016/j.jneuroim.2012.09.014. Epub 2012 Oct 18.
20. Legutki JB, Johnston SA: Immunosignatures can predict vaccine efficacy.
Proc Natl Acad Sci USA 2013, 110(46):18614–18619.
21. Hughes AK, Cichacz Z, Scheck A, Coons SW, Johnston SA, Stafford P:
Immunosignaturing can detect products from molecular markers in
brain cancer. PLoS One 2012, 7(7):e40201.
22. Johnson WE, Li C, Rabinovic A: Adjusting batch effects in microarray
expression data using empirical Bayes methods. Biostatistics 2007,
8(1):118–127.
23. Meyer D, Dimitriadou E, Hornik K, Weingeesel A, Leisch F: e1071: Misc
Functions of the Department of Statistics (e1071), TU Wien. R package
version 1.6-1. 2012.
24. Starrak GS, Berry CR, Page RL, Johnson JL, Thrall DE: Correlation between
thoracic radiographic changes and remission/survival duration in 270
dogs with lymphosarcoma. Vet Radiol Ultrasound 1997, 38(6):411–418.
25. Regan RC, Kaplan MS, Bailey DB: Diagnostic evaluation and treatment
recommendations for dogs with substage-a high-grade multicentric
lymphoma: results of a survey of veterinarians. Vet Comp Oncol 2013,
11(4):287–292.
26. Planinc-Peraica A, Kolonic SO, Radic-Kristo D, Dominis M, Jaksic B: Serum
immunoglobulins in non-Hodgkin’s lymphoma patients. Coll Antropol
2010, 34(2):407–411.
27. Biggar RJ, Christiansen M, Rostgaard K, Smedby KE, Adami H-O, Glimelius B,
Hjalgrim H, Melbye M: Immunoglobulin subclass levels in patients with
non-Hodgkin lymphoma. Int J Cancer 2009, 124(11):2616–2620.
28. Marconato L, Frayssinet P, Rouquet N, Comazzi S, Leone VF, Laganga P,
Rossi F, Vignoli M, Pezzoli L, Aresu L: Randomized, placebo-controlled,
double-blinded chemoimmunotherapy clinical trial in a pet dog model
of diffuse large B-cell lymphoma. Clin Cancer Res 2014, 20(3):668–677.
29. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E,
Roscilli G, Ciliberto G, Aurisicchio L: Safety and efficacy of a genetic
vaccine targeting telomerase plus chemotherapy for the therapy of
canine B-cell lymphoma. Hum Gene Ther 2013, 24(8):728–738.
30. Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH,
Mason NJ: CD40-activated B cell cancer vaccine improves second clinical
remission and survival in privately owned dogs with non-Hodgkin’s
lymphoma. PLoS One 2011, 6(8):e24167.
31. Turek MM, Thamm DH, Mitzey A, Kurzman ID, Huelsmeyer MK, Dubielzig RR,
Vail DM: Human granulocyte-macrophage colony-stimulating factor DNA
cationic-lipid complexed autologous tumour cell vaccination in the
treatment of canine B-cell multicentric lymphoma. Vet Comp Oncol 2007,
5(4):219–231.
32. Yamashita Y, Kajiura D, Tang L, Hasegawa Y, Kinoshita T, Nakamura S,
Akatsuka S, Toyokuni S, Mori N: XCR1 expression and biased VH gene
usage are distinct features of diffuse large B-cell lymphoma initially
manifesting in the bone marrow. Am J Clin Pathol 2011, 135(4):556–564.
33. Warsame AA, Aasheim HC, Nustad K, Troen G, Tierens A, Wang V, Randen U,
Dong HP, Heim S, Brech A, Delabie J: Splenic marginal zone lymphoma
with VH1-02 gene rearrangement expresses poly- and self-reactive
antibodies with similar reactivity. Blood 2011, 118(12):3331–3339.34. Perez M, Pacchiarotti A, Frontani M, Pescarmona E, Caprini E, Lombardo GA,
Russo G, Faraggiana T: Primary cutaneous B-cell lymphoma is associated
with somatically hypermutated immunoglobulin variable genes and
frequent use of VH1-69 and VH4-59 segments. Br J Dermatol 2010,
162(3):611–618.
35. Hashimoto T, Takishita M, Kosaka M, Sano T, Matsumoto T: Superantigens
and autoantigens may be involved in the pathogenesis of gastric
mucosa-associated lymphoid tissue lymphoma. Int J Hematol 2001,
74(2):197–204.
36. Deeb SJ, D’Souza RC, Cox J, Schmidt-Supprian M, Mann M: Super-SILAC
allows classification of diffuse large B-cell lymphoma subtypes by their
protein expression profiles. Mol Cell Proteomics 2012, 11(5):77–89.
37. Stranneheim H, Orre LM, Lehtio J, Flygare J: A comparison between
protein profiles of B cell subpopulations and mantle cell lymphoma
cells. Proteome Sci 2009, 7:43.
38. Felsburg PJ: Overview of immune system development in the dog:
comparison with humans. Hum Exp Toxicol 2002, 21(9–10):487–492.
39. Manz RA, Hauser AE, Hiepe F, Radbruch A: Maintenance of serum antibody
levels. Annu Rev Immunol 2005, 23:367–386.
40. Mumtaz IM, Hoyer BF, Panne D, Moser K, Winter O, Cheng QY, Yoshida T,
Burmester G-R, Radbruch A, Manz RA, Hiepe F: Bone marrow of NZB/W
mice is the major site for plasma cells resistant to dexamethasone and
cyclophosphamide: Implications for the treatment of autoimmunity.
J Autoimmun 2012, 39(3):180–188.
41. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G,
Tedder TF: Maintenance of long-lived plasma cells and serological
memory despite mature and memory B cell depletion during CD20
immunotherapy in mice. J Immunol 2008, 180(1):361–371.
42. Thalheim L, Williams LE, Borst LB, Fogle JE, Suter SE: Lymphoma
immunophenotype of dogs determined by immunohistochemistry, flow
cytometry, and polymerase chain reaction for antigen receptor
rearrangements. J Vet Intern Med 2013, 27(6):1509–1516.
43. Gentilini F, Turba ME, Forni M: Retrospective monitoring of minimal residual
disease using hairpin-shaped clone specific primers in B-cell lymphoma
affected dogs. Vet Immunol Immunopathol 2013, 153(3–4):279–288.
44. Sato M, Yamzaki J, Goto-Koshino Y, Takahashi M, Fujino Y, Ohno K, Tsujimoto H:
The prognostic significance of minimal residual disease in the early phases
of chemotherapy in dogs with high-grade B-cell lymphoma. Vet J 2013,
195(3):319–324.
45. Elliott JW, Cripps P, Blackwood L: Thymidine kinase assay in canine
lymphoma. Vet Comp Oncol 2013, 11(1):1–13.
46. Ratcliffe L, Mian S, Slater K, King H, Napolitano M, Aucoin D, Mobasheri A:
Proteomic identification and profiling of canine lymphoma patients.
Vet Comp Oncol 2009, 7(2):92–105.
doi:10.1186/1471-2407-14-657
Cite this article as: Johnston et al.: The immunosignature of canine
lymphoma: characterization and diagnostic application. BMC Cancer
2014 14:657.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
